The 36-month beta value for ATXI is also noteworthy at -0.27. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATXI is 1.74M, and at present, short sellers hold a 1.29% of that float. The average trading volume of ATXI on January 24, 2025 was 50.44K shares.
ATXI) stock’s latest price update
The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) has dropped by -3.83 compared to previous close of 1.84. Despite this, the company has seen a gain of 1.11% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that – Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 – Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024
ATXI’s Market Performance
ATXI’s stock has risen by 1.11% in the past week, with a monthly drop of -0.03% and a quarterly drop of -16.14%. The volatility ratio for the week is 11.05% while the volatility levels for the last 30 days are 10.27% for Avenue Therapeutics Inc The simple moving average for the last 20 days is -5.71% for ATXI’s stock, with a simple moving average of -44.70% for the last 200 days.
ATXI Trading at -6.64% from the 50-Day Moving Average
After a stumble in the market that brought ATXI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.20% of loss for the given period.
Volatility was left at 10.27%, however, over the last 30 days, the volatility rate increased by 11.05%, as shares sank -2.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.05% lower at present.
During the last 5 trading sessions, ATXI rose by +0.06%, which changed the moving average for the period of 200-days by -84.79% in comparison to the 20-day moving average, which settled at $1.8758. In addition, Avenue Therapeutics Inc saw -11.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATXI starting from Herskowitz Neil, who sale 23 shares at the price of $2.00 back on Dec 02 ’24. After this action, Herskowitz Neil now owns 97 shares of Avenue Therapeutics Inc, valued at $46 using the latest closing price.
KRANZLER JAY D, the Director of Avenue Therapeutics Inc, sale 61 shares at $2.24 during a trade that took place back on Nov 05 ’24, which means that KRANZLER JAY D is holding 559 shares at $137 based on the most recent closing price.
Stock Fundamentals for ATXI
The total capital return value is set at -7.15. Equity return is now at value -1037.72, with -893.00 for asset returns.
Currently, EBITDA for the company is 4.05 million with net debt to EBITDA at 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.70.
Conclusion
In summary, Avenue Therapeutics Inc (ATXI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
